BCAL Diagnostics Limited (ASX:BDX)

Market Cap	25.44M +10.3%
Revenue (ttm)	2.35M -11.2%
Net Income	-7.37M
EPS	-0.02
Shares Out	368.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,610
Open	0.0660
Previous Close	0.0690
Day's Range	0.0660 - 0.0690
52-Week Range	0.0520 - 0.1550
Beta	0.81
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 3, 2026

About BCAL Diagnostics

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTESTplus, a first-in-class blood test designed to be used alongside standard mammogram in breast cancer screening. The company also develops BREASTEST, BCAL Diagnostics, and BCAL Dx. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2010
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: BDX

Financial Performance

In fiscal year 2026, BCAL Diagnostics's revenue was 2.35 million, a decrease of -11.25% compared to the previous year's 2.65 million. Losses were -7.37 million, 1.80% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 4, 2026

Data Sources Report a data error